Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

ALK Abelló shares fall premarket despite strong Q2 growth

ALK Abelló reported currency-adjusted sales growth of 18% in Q2 to around DKK 1.8 billion and EBIT up 19% with a stable EBIT margin of 25%. The company lifted the lower end of its full-year revenue guidance to currency-adjusted growth of 14–16% and expects free cash flow of more than DKK 1 billion. However, investors reacted to missing comparable EPS figures, continued spending on growth initiatives and a more cautious tone for the top end of the guidance, sending the stock down about 6.35% in premarket trading. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2000, ALK-Abelló B has already paid €0.20 in dividends. The last payout was in December 2000.

Financials

In the last quarter, ALK-Abelló B had revenue of €240.15m and net profit of €45.35m

(EUR)	June 2026	YoY
Revenue	240.15m	17.33%
Gross profit	159.88m	19.88%
Net profit	45.35m	28.66%
EBITDA	71.04m	17.78%

Fundamentals

Metric	Value
Market capitalization	€7.34bn
Number of shares	221.88m
52-week high/low	€36.16 - €25.56
Dividends	No
Beta	0.68
P/E ratio	40.72
PEG ratio	1.22
P/B ratio	7.94
P/S ratio	8.07

Company profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.